布西拉明 T21334

Product Introduction
Bioactivity


英文名: Bucillamine

描述: Bucillamine (DE019) 可防止高危器官移植中的缺血/再灌注损伤，抑制 VEGF 的产生。 Bucillamine 是一种具有抗风湿和抗血管生成特性的口服活性巯基供体和抗氧化剂。 Bucillamine 可用于脉络膜新生血管和类风湿性关节炎的研究。

体内活性: In rats subjected to liver transplants, Bucillamine significantly enhances survival and protected against hepatic injury[2]. Subconjunctival injection of Bucillamine significantly reduces the leakage and size of experimental CNV in rats[3].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 25 mg/mL (111.95 mM)


关键字: rheumatoid arthritis | Ischemia/reperfusion | antioxidant | Bucillamine | antirheumatic | inhibit | Inhibitor | VEGFR | SA-96 | antiangiogenic | SA 96 | Vascular endothelial growth factor receptor | choroidal neovascularization

相关产品: (Z)-FeCP-oxindole | JNJ-38158471 | BMS-605541 | Su1498 | Regorafenib Hydrochloride | Acrizanib | SKLB 610 | Decursinol angelate | Pz-1 | MMPP

相关库: Drug Repurposing Compound Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Anti-Ovarian Cancer Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Colorectal Cancer Compound Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Approved Drug Library

布西拉明 T21334信息由TargetMol中国为您提供，如您想了解更多关于布西拉明 T21334报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途